EP2483690A1 - Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation - Google Patents

Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation

Info

Publication number
EP2483690A1
EP2483690A1 EP10760676A EP10760676A EP2483690A1 EP 2483690 A1 EP2483690 A1 EP 2483690A1 EP 10760676 A EP10760676 A EP 10760676A EP 10760676 A EP10760676 A EP 10760676A EP 2483690 A1 EP2483690 A1 EP 2483690A1
Authority
EP
European Patent Office
Prior art keywords
pancreatic
marker sequences
case
marker
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10760676A
Other languages
German (de)
English (en)
Inventor
Peter Amersdorfer
Annabel HÖPFNER
Angelika Lueking
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to EP10760676A priority Critical patent/EP2483690A1/fr
Publication of EP2483690A1 publication Critical patent/EP2483690A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Definitions

  • the present invention relates to novel marker sequences for pancreatic cancers, pancreatic carcinoma and their
  • diagnostic use including a method of screening for potential drugs for such pancreatic cancers by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such
  • Pancreatic carcinoma in particular a protein biochip and its use.
  • pancreatic cancer such as PDAC (Pancreatic ductal adenocarcinoma), PanlN
  • PanIn Pancreatic intraepithelial neoplasia
  • pancreatic lesions pancreatic lesions
  • CP chronic pancreatitis
  • PanIn refers to pancreatic lesions and subdivides them morphologically into Panels 1A, 1B, 2 and 3 (Kern, S., R. Hruban, et al., 2001. "A white paper: the product of a pancreatic cancer think tank.” Cancer Res. 61 (12): 4923-32).
  • Pancreatic lesions are also described for CP.
  • endocrine benign or malignant tumors of the pancreas, especially neuroendocrine tumors.
  • WO2008064670 describes e.g. Marker genes to pancreas, which have been obtained by proteome analysis and histological studies.
  • Protein biochips are gaining an increasing industrial
  • Protein biochips require the necessary proteins to be available. In particular,
  • GATEWAY recombinational cloning application to the cloning of large numbers of open reading frames or ORFeems. Methods Enzymol, 328, 575-592).
  • ORFeems open reading frames
  • Methods Enzymol, 328, 575-592 are strongly related to the progress of the genome sequencing proce- dures and the annotation of these gene sequences.
  • determination of the expressed sequence is due
  • a human cDNA library for high-throughput protein expression screening Genomics, 65, 1-8; Holz, C., Lueking, A., Bovekamp, L., Guther, C., Bolotina, N., Lehrach, H. and Cahill, DJ (2001).
  • the cDNA of a particular tissue in a bacterial or a eukaryotic expression vector, such as yeast, is cloned.
  • the vectors used for the expression are generally characterized by the fact that they carry inducible promoters, with which the timing of protein expression can be controlled.
  • expression vectors have sequences for so-called
  • Affinity epitopes or proteins on the one hand for the specific detection of the recombinant fusion proteins by means of a directed against the affinity epitope
  • Antibody on the other hand becomes the specific one
  • Protein biochips advantageously have a high sensitivity.
  • the object of the present invention is to provide improved marker sequences and their diagnostic use for the treatment of pancreatic cancers to pancreatic carcinoma.
  • SEQ 1 - 1004 new marker sequences, which could be determined for the first time by means of a protein biochip, in particular together with bioinformatory evaluation. Therefore, SEQ 1 - 1004 were first identified using a protein biochip.
  • the invention relates to the use of
  • pancreatic cancers including pancreatic carcinoma, with at least one
  • pancreatic carcinoma can be identified.
  • Pancreatic carcinoma includes a group of diseases and their precursors and / or comorbidities, pancreatic cancer and / or pancreatic carcinoma as such, but in particular PDAC (pancreatic ductal adenocarcinoma), PanlN (pancreatic intraepithelial neoplasia), pancreatic lesions, CP (chronic pancreatitis), including endocrine Tumors of the pancreas, in particular pancreatic tumors and pancreatic neoplasms (definition, for example, according to Pschyrembel, de Gruyter, 261st edition (2007), Berlin).
  • PDAC pancreatic ductal adenocarcinoma
  • PanlN pancreatic intraepithelial neoplasia
  • pancreatic lesions pancreatic lesions
  • CP chronic pancreatitis
  • endocrine Tumors of the pancreas in particular pancreatic tumors and pancreatic neoplasm
  • marker sequences or 50 to 100 or more marker sequences are added to or from one
  • the marker sequences according to the invention can also be combined, supplemented or extended with known biomarkers for this indication.
  • the determination of the marker sequences takes place outside the human body and the determination takes place in an ex vivo / in vitro diagnosis.
  • the invention relates to the use of marker sequences as diagnostic agents, wherein at least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004, or in each case a protein coding therefor or in each case one
  • the invention relates to a method for the diagnosis of pancreatic cancers up to pancreatic carcinoma, wherein a.) At least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004, or in each case a protein coding therefor or each one
  • Partial sequence or fragment thereof is applied to a solid support and b.
  • Tissue extract of a patient is brought into contact and c.)
  • the detection of an interaction of the body fluid or tissue extract with the marker sequences from a.) Is done.
  • the invention also relates to diagnostics for
  • Pancreatic carcinoma selected in each case from the group SEQ 1-1004, preferably SEQ 503-1004, or in each case a protein coding for it or in each case a partial sequence or
  • the detection of such an interaction can, for example, by a probe, in particular by an antibody
  • the invention therefore likewise has the object of providing a diagnostic device or an assay, in particular a protein biochip, which is suitable for the
  • pancreatic cancer to pancreatic cancer a diagnosis or examination allowed. Furthermore, the invention relates to a method for
  • Pancreatic cancer up to pancreatic carcinoma wherein at least one marker sequence of a cDNA selected from the
  • pancreatic cancer to pancreatic cancer in new or established subgroups of pancreatic cancers to pancreatic carcinoma, as well as the judicious selection of patient groups for the clinical development of new
  • therapy control also includes the classification of patients into responders and non-responders with regard to a therapy or its course of therapy.
  • pancreatic cancers to pancreatic carcinoma.
  • diagnosis includes medical diagnosis and related investigations, especially in vitro
  • diagnosis also includes the
  • pancreatic carcinoma by means of the marker sequences of the invention and the prognosis of pancreatic cancers,
  • the term "stratification" includes in particular the
  • patient is understood to mean any subject - human or mammal - with the proviso that the subject is examined for pancreatic cancers up to pancreatic carcinoma.
  • marker sequences in the sense of this invention means that the cDNA or the respectively obtainable polypeptide or protein significantly for
  • pancreatic cancers pancreatic carcinoma.
  • the cDNA or each of them are examples of them.
  • pancreatic carcinoma eg, antigen (epitope) / antibody (paratope) interaction
  • at least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004, or in each case one protein coding for this or one each
  • Partial sequence or fragment thereof is determined on a patient to be examined "that an interaction between the body fluid or tissue extract of a patient and the marker sequences according to the invention is detected, for example, a bond, in particular a binding substance to at least one of the invention
  • Marker sequence or, in the case of a cDNA, hybridization with a suitable substance under selected conditions, in particular stringent conditions (for example, as usual
  • Hybridization conditions is hybridization in 4 x SSC at 37 ° C followed by several washing steps in 1 x SSC
  • Body fluid in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid or a tissue extract of the patient.
  • the marker sequences according to the invention may be present at a significantly higher or lower expression rate or concentration, which has an effect on the pancreatic cancers, Pancreatic carcinoma indicates.
  • the relative expression rate or concentration which has an effect on the pancreatic cancers, Pancreatic carcinoma indicates.
  • Pancreatic carcinoma determined.
  • the marker sequences have in a further embodiment of the invention a
  • the recognition signal for a protein is preferably an epitope and / or paratope and / or hapten and, for a cDNA, a hybridization or binding region.
  • Sequences 503 to 1004 are preferred sequences which have been determined directly with the protein biochip according to the invention.
  • the marker sequences also include such
  • Amino acid sequence such as chemical modification, such as
  • marker sequences In particular, such subsequences, which have an identity of 95%, 90%, in particular 80% or 70% with the marker sequences according to the invention.
  • Such partial sequences or fragments of the marker sequences according to the invention are functionally defined and have the same diagnostic function.
  • Subsequences are therefore also those sequences which have 50 to 100 nucleotides, 70-120 nucleotides of a sequence of SEQ 1-1004, preferably SEQ 503-1004, or peptides obtainable therefrom.
  • sequences which have 50 to 100 nucleotides, 70-120 nucleotides of a sequence of SEQ 1-1004, preferably SEQ 503-1004, or peptides obtainable therefrom.
  • the respective amino acids amino acids
  • Marker sequence can be represented in different amounts in one or more areas on a solid support. This allows a variation of the sensitivity.
  • the regions may each comprise a total of marker sequences, i. a sufficient number of different marker sequences, in particular 2 to 5 or 10 or more and optionally further nucleic acids and / or proteins, in particular biomarkers.
  • Biomarkers Further preferred are more than 2,500, more preferably 10,000 or more different or the same
  • Marker sequences and optionally other nucleic acids and / or proteins, in particular biomarkers are optionally other nucleic acids and / or proteins, in particular biomarkers.
  • Another object of the invention relates to an arrangement of marker sequences containing at least one marker sequence of a cDNA selected from the group SEQ 1 - 1004,
  • the arrangement contains at least 2 to 5 or 10, preferably 30 to 50
  • “arrangement” synonymously means “array” and insofar as this "array” is used to identify substances on marker sequences, this is to be understood as meaning an “assay” or a diagnostic device.
  • the arrangement is designed such that those represented on the assembly
  • Marker sequences in the form of a grid on a solid support are preferred which include a high density array of protein binders
  • Such high density spotted assemblies are disclosed, for example, in WO 99/57311 and WO 99/57312, and may be advantageously used in a robotic automated high throughput method.
  • say or diagnostic device also includes such
  • Embodiments of a device such as ELISA, bead-based assay, line assay, Western blot, immunochromatographic
  • Invention is the systematic arrangement of proteins on a solid support.
  • the marker sequences of the assembly are fixed to a solid support, but preferably spotted or immobilized even printed, that is applied reproducibly.
  • One or more marker sequences can be duplicated in the totality of all Marker sequences are present and available in different quantities based on a spot. Furthermore, the
  • Marker sequences on the solid support e.g., by serial dilution series of e.g.
  • the invention relates to an assay or protein biochip consisting of an array containing marker sequences according to the invention.
  • the marker sequences are present as clones.
  • Such clones can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al., 1998 (supra)).
  • such expression libraries become
  • These expression vectors preferably contain inducible promoters. The induction of
  • Expression can e.g. by means of an inductor, such as IPTG.
  • IPTG inductor
  • Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol 2003 Jan; 60 (5): 523-33).
  • Expression libraries are known to the person skilled in the art, these can be prepared according to standard works, such as Sambrook et al., Molecular Cloning, Laboratory Handbook, 2nd edition (1989), CSH press, Cold Spring Harbor, New York Further preferred are such expression libraries
  • tissue specific eg human tissue, especially human organs.
  • expression libraries are also included according to the invention, which by means of exon Trapping can be obtained.
  • expression library can be spoken synonymously from an expression bank.
  • Uniclone® library protein biochips or corresponding expression libraries which have no redundancy
  • Uniclone® library protein biochips or corresponding expression libraries which have no redundancy
  • These preferred Uniclone libraries have a high content of non-defective, fully expressed proteins of a cDNA expression library.
  • the clones may not be such as transformed bacteria, recombinant phage or transformed cells of mammals, insects, fungi, yeasts or plants.
  • the clones are fixed on a solid support, spotted or immobilized.
  • the invention relates to an arrangement, wherein the
  • Marker sequences are present as clones.
  • marker sequences may be in the form of a fusion protein in the particular form
  • At least one affinity epipope or "tag” contains.
  • the tag may be one such as c-myc, His-tag, Arg-tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or Strep tag, HAT tag, NusA, S-tag, SBP tag , Thioredoxin, DsbA, a fusion protein, preferably a cellulose-binding one
  • Protein Protein, calmodulin-binding protein, glutathione S-transferase or lacZ.
  • solid support includes embodiments such as a filter, a membrane, a magnetic or fluorophore-labeled bead, a
  • a filter is preferred according to the invention. Also preferred as the filter is PVDF, nitrocellulose or nylon (e.g., Immobilon P Millipore, Protran Whatman, Hybond N + Amersham).
  • this corresponds to a grid having the order of a microtiter plate (8-12 wells strips, 96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
  • the invention relates to an assay or protein biochip for identifying and
  • inventive arrangement or assay with a.) At least one substance to be examined is brought into contact and b.) A binding success is detected.
  • the invention relates to a method for identifying and characterizing a substance for
  • pancreatic cancer pancreatic carcinoma
  • an arrangement or assay according to the invention is brought into contact with a.) at least one substance to be investigated and b.) a binding success is detected.
  • the substance to be tested may be any native or non-native biomolecule, a synthetic chemical
  • protein to marker sequence e.g., protein to marker sequence
  • Antigen / antibody or corresponding "means for detecting the binding success" can, for example, by means of
  • reporter enzymes such as alkaline
  • a readout is e.g. by means of a microarray laser scanner, a CCD camera or visually.
  • the invention relates to a drug / drug or prodrug for
  • pancreatic cancer, pancreatic carcinoma developed and available by the use of the assay or protein biochip according to the invention. Therefore, the invention also relates to the use of an arrangement according to the invention or an assay for the screening of active substances for pancreatic cancer diseases, pancreatic carcinoma.
  • the invention also relates to a target for the treatment and therapy of
  • pancreatic cancers pancreatic carcinoma, respectively
  • SEQ 1 - 1004 selected from the group SEQ 1 - 1004, preferably SEQ 503 - 1004, or in each case a protein coding therefor.
  • the invention also relates to the use of the invention
  • Marker sequences preferably in the form of an arrangement, as an affinity material for performing an apheresis or iwS. a blood wash, wherein substances from bodily fluids of a patient with pancreatic cancers,
  • Pancreatic carcinoma such as blood or plasma
  • pancreatic cancer, pancreatic carcinoma-specific expression clones were identified by comparison with ten or more healthy specimens. The identity of
  • Protein biochips each from a cDNA expression library of a patient and a healthy subjects shown. The
  • Differential clones are detected by fluorescence labeling and evaluated bioinformatorisch.
  • biomarker identification various bioinformatic analyzes are carried out. For each serum, microarray reactivities against about 2000
  • Intensity data performed.
  • an internal standard is used, which is spotted on each chip. Since a p-value is calculated for each antigen, methods for correcting multiple testing are used. As a very conservative approach, a Bonferroni correction is performed and, in addition, the less restrictive False Discovery Rate (FDR) is calculated according to Benjamini & Hochberg.
  • FDR False Discovery Rate
  • the data are used to classify the sera.
  • different multivariate methods are used. These are methods from the statistical
  • Threshold method which is suitable for both classification and visual representation of the data.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouvelles séquences de marqueurs pour les affections cancéreuses du pancréas, le carcinome pancréatique, et leur utilisation en diagnostic ainsi qu'un procédé de dépistage de principes actifs potentiels de telles affections du pancréas à l'aide desdites séquences de marqueurs. L'invention concerne également un dispositif de diagnostic contenant de telles séquences de marqueurs pour les affections cancéreuses du pancréas, le carcinome pancréatique, notamment une biopuce à protéine et son utilisation.
EP10760676A 2009-09-29 2010-09-29 Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation Withdrawn EP2483690A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10760676A EP2483690A1 (fr) 2009-09-29 2010-09-29 Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09171690 2009-09-29
PCT/EP2010/064510 WO2011039289A1 (fr) 2009-09-29 2010-09-29 Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation
EP10760676A EP2483690A1 (fr) 2009-09-29 2010-09-29 Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation

Publications (1)

Publication Number Publication Date
EP2483690A1 true EP2483690A1 (fr) 2012-08-08

Family

ID=43103499

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10760676A Withdrawn EP2483690A1 (fr) 2009-09-29 2010-09-29 Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation

Country Status (4)

Country Link
US (1) US20120264634A1 (fr)
EP (1) EP2483690A1 (fr)
CA (1) CA2775978A1 (fr)
WO (1) WO2011039289A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510002A (ja) 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
CN107102142A (zh) 2007-03-27 2017-08-29 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA2780069C (fr) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Anticorps monoclonaux contre la proteine rgm a destines a etre utilises dans le traitement de la degenerescence de la couche de fibres nerveuses retiniennes
MY194587A (en) 2012-01-27 2022-12-05 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP3011334A1 (fr) * 2013-06-20 2016-04-27 The Trustees Of The University Of Pennsylvania Méthodes permettant de diagnostiquer un cancer du pancréas
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US11099185B2 (en) 2016-02-29 2021-08-24 Maintect Gmbh Predictive markers useful in the treatment of wet age-related macular degeneration
KR102111699B1 (ko) * 2017-09-05 2020-05-15 (주)온코태그디아그노스틱 메티오닐-티알엔에이 합성효소를 이용한 췌장암 진단 방법 및 이를 이용한 췌장암 진단 키트
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326390A1 (fr) 1998-04-30 1999-11-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nouveau procede permettant l'identification de clones conferant une propriete biologique desiree dans une banque d'expression
JP2002513589A (ja) 1998-04-30 2002-05-14 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 再アレー化を伴う、発現ライブラリーのクローンを選択するための新規方法
US20050277137A1 (en) * 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
CA2660286A1 (fr) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Proteines specifiques d'organes et procedes d'utilisation
WO2008063479A2 (fr) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Biomarqueurs du cancer du pancréas
DE102006056784A1 (de) 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
US20100144538A1 (en) * 2007-03-08 2010-06-10 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
EP2135080A4 (fr) * 2007-03-08 2010-12-01 Switchgear Genomics Reseaux fonctionnels pour la caracterisation de traitement d'elements de regulation dans des regions non traduites de genes
EP2253715A1 (fr) * 2009-05-14 2010-11-24 RWTH Aachen Nouvelles cibles pour la thérapie et/ou le diagnostic du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011039289A1 *

Also Published As

Publication number Publication date
US20120264634A1 (en) 2012-10-18
WO2011039289A1 (fr) 2011-04-07
CA2775978A1 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
EP2483690A1 (fr) Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation
EP2795332A2 (fr) Séquences de marqueurs du cancer du sein et utilisation desdites séquences de marqueurs du cancer du sein
WO2013087929A2 (fr) Procédé d'identification de séquences de marqueurs pour le cancer gynécologique
WO2009030226A2 (fr) Séquences de marqueurs de la polyarthrite rhumatoïde et leur utilisation
WO2012049225A2 (fr) Séquences de marqueur pour lupus érythémateux systémique et leurs utilisations
WO2010000874A2 (fr) Séquences de marqueurs pour maladies inflammatoires de la prostate, le cancer de la prostate, et leurs utilisations
EP2622350A2 (fr) Séquences de marqueurs pour la sclérose multiple et utilisation desdites séquences de marqueurs
WO2009080017A2 (fr) Séquences de marqueurs pour des maladies neurodégénératives et leur utilisation
WO2013170994A1 (fr) Séquences marqueurs de la polyarthrite rhumatoïde
WO2009030225A2 (fr) Séquences de marqueurs de la sclérose en plaques et leur utilisation
EP2745115B1 (fr) Nouveau procédé de diagnostic de liants de haute affinité, et séquences de marqueur
WO2012049228A2 (fr) Séquences de marqueur pour la sclérose en plaques et leur utilisation
DE102007041656A1 (de) Markersequenzen für rheumatoide Arthritis und deren Verwendung
WO2012107596A2 (fr) Séquences de marqueurs pour le diagnostic du cancer de la prostate et leur utilisation
WO2008092442A1 (fr) Stratification et commande thérapeutique d'un patient au moyen de biopuces protéiniques
WO2013072393A2 (fr) Nouveau procédé d'identification de séquences de marqueurs spécifiques pour le cancer de la prostate
WO2011006909A2 (fr) Séquences de marqueurs de l'obésité et utilisation de ces séquences
DE102015108523A1 (de) Peptid-Biomarker für Krebs
DE102007041654A1 (de) Markersequenzen für juvenile idiopathische Arthritis und deren Verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140225

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140508